Financial Performance - The company's operating revenue for 2022 was ¥2,000,975,899.68, a decrease of 3.42% compared to ¥2,071,740,062.67 in 2021[22]. - Net profit attributable to shareholders increased by 11.60% to ¥202,948,039.69 in 2022 from ¥181,849,264.51 in 2021[22]. - The net profit after deducting non-recurring gains and losses rose by 54.30% to ¥225,892,277.97 in 2022 compared to ¥146,401,786.78 in 2021[22]. - Total assets at the end of 2022 were ¥4,008,418,399.76, reflecting a 5.32% increase from ¥3,806,025,067.11 at the end of 2021[22]. - The company's net assets attributable to shareholders increased by 9.80% to ¥2,387,566,980.33 at the end of 2022 from ¥2,174,390,029.16 at the end of 2021[22]. - The total revenue for the year 2022 was CNY 2,000.98 million, a decrease of 3.42% compared to the previous year[46]. - The net profit attributable to shareholders was CNY 202.95 million, an increase of 11.60% year-on-year[46]. - Revenue from the chemical industry was approximately $1.84 billion, accounting for 91.83% of total revenue, down 4.82% year-over-year[50]. - Revenue from the environmental protection industry increased by 15.75% to approximately $163.40 million, representing 8.17% of total revenue[50]. - Sales of pesticide intermediates decreased by 15.72% to approximately $1.20 billion, accounting for 60.06% of total revenue[50]. - Sales of pharmaceutical intermediates increased by 30.07% to approximately $441.62 million, representing 22.07% of total revenue[50]. Cash Flow and Investments - The net cash flow from operating activities significantly decreased by 80.82% to ¥81,067,227.82 in 2022 from ¥422,704,008.77 in 2021[22]. - The company reported a significant decline in cash flow from operations in Q1 2022, with a net cash flow of -¥108,978,197.34[24]. - Operating cash inflow decreased by 20.07% to ¥1,744,731,071.50, primarily due to a 20.73% drop in cash received from sales[67]. - The net increase in cash and cash equivalents was a decrease of 477.53%, resulting in a net decrease of ¥134,888,263.18[68]. - The total investment amount for the reporting period was 17 million yuan, representing a 70% increase compared to 10 million yuan in the same period last year[77]. - The company made significant equity investments, including a 100% stake in Lanzhou Yaben Chemical Co., with an investment amount of 7,000,000 CNY[78]. - The total amount of foreign exchange contracts at the end of the reporting period was 35,774.26 million CNY, representing 0.85% of the company's net assets[82]. - The company has established a derivative investment management system to mitigate risks associated with foreign exchange fluctuations[83]. Research and Development - The company has invested significantly in R&D, leading to optimized processes and a strong competitive position in the market[40]. - The company’s R&D investment ratio is among the top in the industry, focusing on innovative pesticides and pharmaceuticals[44]. - The company is focusing on enhancing its R&D capabilities and expanding its market presence through strategic project adjustments[94]. - Continuous investment in R&D is planned, with a focus on synthetic biology and green chemistry to enhance the company's competitive edge[111]. - The company is actively expanding its product offerings in the fields of anti-tumor and anti-pathogen areas through strategic R&D initiatives[37]. Market Position and Strategy - The company is positioned to benefit from the ongoing consolidation in the pesticide industry, with a focus on environmentally friendly products[33]. - The company has a market share of 50-60% for its bromoxynil products, which are recognized as high-efficiency and environmentally friendly pesticides[40]. - The company aims to expand its market reach through new product registrations and maintaining compliance with regulatory standards[42]. - The company plans to delay the new production line project in Nantong to July 2023, and the enzyme preparation and green research institute projects to May 2023[94]. - The company plans to use the remaining funds from terminated projects for the enzyme preparation and green research institute project[97]. Environmental Compliance - The company adheres to various environmental protection laws and regulations, ensuring compliance in its production processes[161]. - The company has obtained pollution discharge permits valid until December 2025 and November 2027 for its subsidiaries[162]. - The company has implemented comprehensive waste treatment facilities to minimize environmental impact[161]. - The company reported a total wastewater discharge of 15.847 tons per year, with a COD concentration of 70 mg/L, exceeding the regulatory limit[163]. - The company has established a monitoring system for wastewater discharge to ensure it remains within regulatory limits[165]. Corporate Governance - The company has a governance structure in place with a clear distinction of roles among directors and management[128]. - The company appointed a new deputy general manager and board secretary, Wang Yichuan, on December 19, 2022[129]. - The company has a structured approach to board member appointments and departures, ensuring continuity in governance[129]. - The company reported a total shareholding of 271.0 million shares, with no changes in the number of shares held by directors and supervisors during the reporting period[128]. - The company has not reported any changes in the voting rights of preferred shareholders[127]. Employee Management - The total number of employees at the end of the reporting period was 1,038, with 191 in the parent company and 847 in major subsidiaries[146]. - The employee training program includes both internal and external training to enhance professional skills and management levels, aligning with the company's sustainable development needs[149]. - The company has a performance-oriented compensation management system to motivate employees and attract talent, considering industry salary levels and overall company performance[148]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 5.5465 million yuan[136]. Risk Management - The company faces risks from macroeconomic fluctuations and stringent environmental regulations, which may impact financial performance[114]. - To mitigate risks, the company will enhance its operational resilience and invest in environmental compliance measures[115]. - The company faces potential negative impacts on gross margin and profitability due to fluctuations in raw material prices, which are influenced by market supply and demand[116]. - The company is enhancing its cost management system and exploring new procurement models to ensure supply chain stability and optimize procurement costs[116]. Legal and Regulatory Matters - The company is involved in a legal case with a claim amount of 4.4865 million yuan related to securities false statements, which is expected to have no significant impact on its performance[198]. - The company faced disciplinary actions for violations of the Shenzhen Stock Exchange listing rules, resulting in public reprimands for multiple executives[200]. - The violations included breaches of specific articles in the revised listing rules effective December 2020[200].

证券代码：300261 证券简称：雅本化学 公告编号：2023-018 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 雅本化学股份有限公司（以下简称"公司"）2022年年度报告及摘要于2023年4 月26日刊登于中国证监会指定的创业板信息披露网站。 为使投资者能够进一步了解公司2022年度经营情况，公司将于2023年5月16日 （星期二）下午15：00-17：00在全景网举办2022年度业绩说明会。本次说明会将采 用网络远程的方式举行，投资者可登录"全景路演"（http://rs.p5w.net）参与本次 年度业绩说明会。 出席本次说明会的人员有：公司董事长、总经理蔡彤先生；财务总监王爱军先 生；董事会秘书王一川先生；独立董事饶艳超女士。 为充分尊重投资者、提升交流的效率和针对性，公司现就2022年度业绩说明会 提前向投资者公开征集问题，广泛听取投资者意见和建议。投资者可于2023年5月15 日（星期一）15:00前访问问题征集专题页面（http://ir.p5w.net/zj/）。公司将对征集 到的问题进行整理，于2022年度业绩说明会上对投资者普遍关注的 ...

雅本化学股份有限公司 投资者关系活动记录 日期：2015 年 5 月 11 日 地点：公司会议室 参加人员： 雅本化学：王卓颖、马立凡、朱佩芳 ·江苏证监局：乔颖 ·江苏省上市公司协会：旷野 ·华夏基金：倪淼 ·太平资产：周小波 ·淡水泉投资：叶智深、黄垲锐 ·毕盛资产：林建军 ·东吴证券：崔檬、沈倩、高红梅、肖晶群 ·个人投资者 17 名 调研纪要： 董事会秘书王卓颖女士、董事马立凡先生、证券事务代表朱佩芳女士欢迎各 位来到雅本化学参加"江苏上市公司诚信自由行活动"。 董事会秘书王卓颖女士对公司情况进行了介绍： 一、雅本的理念："卓越与远见" 1、所谓卓越，包括四点： ⑴ 高端定制，公司为大型国际农药、医药公司（包括罗氏、拜耳、BI，强生 等）的创新产品提供关键中间体的高端定制，享受其专利期内的高速增长。 ⑵ 研发创新，三大类，十项核心技术，26 项已授权专利，17 项已授理专 利，10 项专利进行了 PCT 申请。 ⑶ 产品销售，公司产品销售势头强劲，2014 年营业收入达 5.26 亿，实现 了跨越式增长，2015 年将会大幅增长； ⑷ 雅本制造，将雅本制造打造成高端制造的代名词。 2、所谓远见，包括广 ...

雅本化学股份有限公司 调研会议纪要 日期：2014 年 12 月 24 日 地点：公司会议室 参加人员： 雅本化学：王卓颖、毛海峰 ·兴业全球基金：朱璘 ·中海基金：易小金 ·国信证券：李云鑫 ·东方证券资产管理：蔡志鹏 ·华富基金：许一 调研纪要： 董事会秘书王卓颖、副总经理毛海峰欢迎各位来公司位于南通洋口的生产 基地即公司控股的子公司南通雅本化学有限公司进行调研，并带领各位到公司 厂区进行了参观，介绍了公司整体的规划情况和未来的布局。除辅助的车间和 中控区域，重点参观了投入运行的 101 车间和 205 车间。 1、南通雅本未来发展 南通雅本以国际标准建设的高端中间体生产基地，而新开工的 BPP 生产线 更是标志着雅本向"工业 4.0"迈进。南通雅本目前已有两条生产线投入试生产， 均采用机械自动化来替代原本的人工流水线作业，减少人员干预，仅需要少量 操作员即可完成整个生产流程；而新车间更是智能化的运行，数据直接进入客 户的全球供应链网络。雅本在智能系统上的投资超过了生产装置的投资，全面 采用先进的 DCS 设备进行全程管控，自动化生产的同时智能化采集生产数据， 并能快速、及时地与客户进行交互反馈，充分发挥 ...

雅本化学股份有限公司 调研会议纪要 日期：2017 年 5 月 17 日 地点：公司会议室 参加人员： 雅本化学：蔡彤、王卓颖、朱佩芳 中泰证券： 罗雅婷 海通证券： 王鸣阳、孙健 富国基金： 燕云 中金公司： 贾雄伟 明溪资产： 王柯 天街投资： 周庆芳 华宝基金： 周阳 国泰基金： 金烨 睿郡资产： 杜昌勇 华创证券： 刘和勇 兴聚投资： 张建萍 | --- | --- | |-----------------|-------------------| | | | | 东北证券： 付赫 | | | | 西南证券： 李迪心 | | | | | 国金证券： 霍堃 | | | | 天弘基金： 杨大志 | 调研纪要： 董事长蔡彤先生、董事会秘书王卓颖女士、证券事务代表朱佩芳女士欢迎 各位来到上海雅本张江创新中心参加调研活动。 一、董事长介绍公司情况： 雅本化学定位于精细化工领域高级中间体定制服务企业。上市六年来，业 务层面、技术层面和平台方面三大变化。 业务方面：农药中间体和医药中间体高端定制生产，从上市前 1.8 亿的销 售收入到 2016 年 6.6 亿，"3+3"布局，即三个研发中心和三个生产基地基本 完成 ...

雅本化学股份有限公司 投资者关系活动纪要 日期：2017 年 8 月 3 日 地点：公司会议室 参加人员：雅本化学：蔡彤、王博、江岳恒、Gianluca Di Lernia、朱佩芳 蒂法马梵思：Marc-Olivier Geinoz、Stefano Paolo Lombardi AMINO：Antonio Sommei 睿郡资产： 杜昌勇 天弘基金： 杨大志 招商证券：于庭泽、孙维容 中信建投：罗婷 华富基金：邓详 光大证券：赵龙 万家基金：耿嘉洲 申万宏源：周波 璞智投资：温灵军 宽华投资：唐春华 茂硕资产：王烨华 新活力资本：黄凯锐 上海德汇：张英杰 证券时报：邓亮 机会宝：雷震昊 活动纪要： 雅本化学股份有限公司（以下简称"雅本化学"或"公司"）董事长蔡彤 先生与意大利蒂法马梵思股份有限公司（以下简称"蒂法马梵思"）首席执行 官 Marc-Olivier Geinoz 先生及两家公司的管理人员共同出席活动，并对各位 投资者来到上海雅本张江创新中心参加调研活动表示了热烈的欢迎。 活动中，蔡彤先生与 Geinoz 先生对雅本化学并购原蒂法马梵思旗下的 Amino Chemicals Limited (以下简 ...

雅本化学股份有限公司 调研会议纪要 日期：2018 年 1 月 9 日 地点：公司会议室 参加人员： 雅本化学：蔡彤、王卓颖、朱佩芳 招商证券： 谢笑妍、于庭泽 银河基金： 包武斌 睿郡资产：沈晓源 中财生生资本： 曲文超、刘毅 | --- | --- | |-------------------|--------| | | | | 启明创投： 陈勇辰 | | | 新华基金： 崔古昕 | | | | | | 尚近投资： 万鹏杰 | | | 光大证券： 殷中枢 | | | 中域资产： | 袁鹏涛 | 调研纪要： 董事长蔡彤先生、董事会秘书王卓颖女士、证券事务代表朱佩芳女士欢迎 各位来到上海雅本张江创新中心参加调研活动。 一、董事长介绍公司情况： 雅本化学主要从事农药中间体和医药中间体高端定制生产。目前公司拥有 太仓、南通、盐城和马耳他四个制造基地，其中马耳他 ACL 是我们 2017 年 6 月底并购的首个海外子公司，主要从事高端原料药定制生产业务。 南通基地是公司的主要制造基地，总投资超七亿元，2013 年开工建设， 2015 年 12 月投产，2017 便实现了 6 亿多的营收，2018 年预计仍将保持高 ...

雅本化学股份有限公司投资者关系活动记录表 证券代码：300261 证券简称：雅本化学 编号：2021-05-01 | --- | --- | --- | |-----------------------|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 | √业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他 | | 参与单位名称及 | 通过全景网 " | ...

雅本化学股份有限公司投资者关系活动记录表 证券代码：300261 证券简称：雅本化学 编号：2021-07-01 | --- | --- | --- | |-----------------------------|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | √特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他 | | 参与单位名称及 人员姓名 | 富安达基金：栾庆帅 财通证券 ...

雅本化学股份有限公司投资者关系活动记录表 证券代码：300261 证券简称：雅本化学 编号：20211026 | --- | --- | --- | |-----------------------|-----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n□业绩说明会 \n□路演活动 \n□其他 | | 参与单位名称及 | 平安资管：陈煜 | | | 人员姓名 | 九禄投资：王飞飞 | | | 时间 | 2021 年 10 月 26 日 | 15:30 | | ...